1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone has been researched along with ym 022 in 1 studies
| Studies (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Trials (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Recent Studies (post-2010) (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Studies (ym 022) | Trials (ym 022) | Recent Studies (post-2010) (ym 022) |
|---|---|---|---|---|---|
| 26 | 0 | 5 | 65 | 1 | 8 |
| Protein | Taxonomy | 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone (IC50) | ym 022 (IC50) |
|---|---|---|---|
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | 0.146 | |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, XQ; Håkanson, R | 1 |
1 other study(ies) available for 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and ym 022
| Article | Year |
|---|---|
Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
Topics: Analysis of Variance; Animals; Anti-Ulcer Agents; Benzodiazepines; Benzodiazepinones; Dose-Response Relationship, Drug; Female; Gastric Emptying; Gastric Mucosa; Histidine Decarboxylase; Hormone Antagonists; Infusions, Intravenous; Lethal Dose 50; Male; Mice; Phenylurea Compounds; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Structure-Activity Relationship | 1996 |